Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NSRX with free AI briefings, catalyst countdowns, and dilution alerts.

NSRX · Nasus Pharma Ltd

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$11.8M Cash on Hand
13.5mo Cash Runway
Follow NSRX by email Get an email when NSRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NSRX, unsubscribe in one click. Privacy

📣 What NSRX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
B: FMXIN002 3.6mg Anaphylaxis Phase 1/2 · NCT06205134 Completed
C: FMXIN002 4.0mg Anaphylaxis Phase 1/2 · NCT06205134 Completed
FMXIN002 double dose Anaphylaxis Phase 1/2 · NCT07228325 Enrolling by invitation
Acetylcysteine Anaphylaxis Phase 1/2 · NCT07228325 Enrolling by invitation
FMXIN002 single dose Anaphylaxis Phase 1/2 · NCT07228325 Enrolling by invitation
Epinephrine Nasal Product Anaphylaxis Phase 1 · NCT04696822 Completed

Also used in these trials (approved or third-party drugs, not NSRX's own candidates): Epinephrine, NS003 Ondansetron HCl microspheres powder for nasal application, Ondansetron Solution for IV infusion 8mg.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NSRX holds $11.8M in cash and short-term investments and burns about $2.6M/quarter from operations, an estimated runway of 13.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 43 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NSRX files for a raise →

👥 Who Owns NSRX

Insiders 59% Other 5%+ holders 6.8% Institutions (10 holders) 18.4% Public and other holders 15.8%
HolderTypeShares% of sharesAs of
Udi Gilboa
Founder & Executive Chairman
Insider 1,924,476 21.35% 2026-03-18
Dalia Megiddo
Chief Development Officer, Director
Insider 1,894,068 21.01% 2026-03-18
Ronnie Hershman
Director
Insider 1,338,463 14.85% 2026-03-18
BALYASNY ASSET MANAGEMENT L.P. Institution (13G, 5%+) 1,170,209 12.98% 2026-09-30
Funicular Funds, LP 5%+ holder (13G) 612,913 6.80% 2026-03-31
Dan Benjamin Teleman
Chief Executive Officer, Director
Insider 163,541 1.81% 2026-06-17

Share count 9,015,383 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NSRX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NSRX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.